Posts Tagged CDMO

Up and Away, M&A

by

Mergers and acquisitions are positive for the CDMO industry, but there is a downside. Mergers and acquisitions (M&A) are a central feature of the contract development and manufacturing (CDMO) industry today. Several new deals are being announced every month, some of them quite substantial, and these deals are reshaping the industry. CDMOs are in great […]

Learn more

Contract Manufacturing Through the Years

by

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold? The 40 years during which Pharmaceutical Technology has served the bio/pharmaceutical industry have been years of momentous growth and change in the way drugs are discovered, developed, manufactured, and sold. Contract development and manufacturing organizations (CDMOs) have long […]

Learn more

AMRI Sold to PE Firms

by

Albany Molecular Research Inc. (AMRI) is being taken private in a deal that values the company at $922 million. The buyers, private equity firms The Carlyle Group and GTCR, are newcomers to the contract development and manufacturing organization (CDMO) space, although Carlyle also owns clinical contract research organization (CRO) PPD Inc. The investors are paying […]

Learn more

Big Pharma Capex Continues to Grow, but Rate Slows

by

Spending by global bio/pharmaceutical companies on new plant and equipment grew by an average of 2.7% in 2016, compared to sales growth of 4.4% (see Figure 1, below). This is the first year in recent times that revenue growth has outpaced capex growth. Moreover, the increase in capital expenditure represented a significant decline from the […]

Learn more

2016 Results Summary: A Rising Tide Lifts All Contract Service Boats

by

The Contract Development and Manufacturing Organization (CDMO) sector enjoyed a strong 2016, with all components reporting robust, albeit uneven, growth. Early-stage companies posted especially impressive results, bolstered by generous external funding, and the API sector continued its recent recovery, especially in the small molecule space (see Figure 1, below). The impressive top line results do, […]

Learn more

NDA Outsourcing Up, Despite NME Decline

by

In 2016, outsourced dose form manufacturing of NDA approvals reached 60%, some 10% higher than the five-year average. This and other insights into CMO performance were revealed in PharmSource’s recently published CMO Scorecard. In what proved to be a mediocre year for drug approvals, the increase in outsourcing levels was restricted to the manufacture of […]

Learn more

Bio/Pharmaceutical Outsourcing Report – Special DCAT 2017 Edition

by

PharmSource has published a special DCAT Edition of our proprietary industry briefing, Bio/Pharmaceutical Outsourcing Report. This monthly report reports on and analyzes major developments throughout the CMO industry. It provides expert insight into the significance of industry trends and what they mean for your business. Deepen your understanding of what’s happening in commercial and clinical […]

Learn more

Time to Hit the Road!

by

The pharma trade show season is officially in full swing! Whether your organization is a CRO, CMO, CDMO or any other service provider to the pharma/biotech/device and diagnostics industry, chances are you’ve either recently attended, or will be attending, an industry event over the next few months. If this is the case, make sure you’re […]

Learn more

The Tide Stays High

by

Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017. A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% […]

Learn more

Is R&D Productivity Improving?

by

In the past few years, approvals of new drugs have reached levels not seen for decades. The superficial reasons for this are clear: a combination of benign financial market conditions that have enabled companies to raise substantial amounts of cash, and regulatory authorities in Europe and the US that are committed to ensuring that novel […]

Learn more